Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report announces a significant regulatory milestone: the US Food and Drug Administration (FDA) approval of BREO ELLIPTA, a combination inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only specific financial figure disclosed is a contractual milestone payment.
- Milestone Payment: Theravance, Inc. is obligated to pay GSK $30 million (USD) following the FDA approval of BREO ELLIPTA under their 2002 collaboration agreement.
Material Changes
The primary material change is the regulatory approval of BREO ELLIPTA (fluticasone furoate/vilanterol) in the United States. This approval enables GSK to commercialize the product as a once-daily maintenance treatment for airflow obstruction in COPD patients and to reduce exacerbations. The filing notes that the product is not yet approved in the European Union or Japan.
Guidance, Outlook, and Risks
Commercial Outlook: GSK anticipates that BREO ELLIPTA will be available in the US market during the third quarter of 2013.
Risks and Safety Information: The filing includes significant safety warnings and contingencies:
- Contraindications: Not for use in patients with severe hypersensitivity to milk proteins or the active ingredients. Not for acute bronchospasm or asthma treatment.
- Adverse Events: Increased incidence of pneumonia (including fatal cases) observed in clinical trials. Other risks include oropharyngeal candidiasis, adrenal suppression, and potential cardiovascular effects.
- Class Effect Warning: Long-acting beta 2-agonists (LABAs) like vilanterol carry a risk of asthma-related death; the drug is not indicated for asthma.
- Forward-Looking Statements: GSK and Theravance caution that actual results may differ from projections due to regulatory delays, clinical study outcomes, and manufacturing dependencies.
Investor Verification Checklist
- Verify the timing of the $30 million milestone payment receipt from Theravance.
- Monitor the actual US launch date in Q3 2013 against the anticipated schedule.
- Review post-market safety data regarding pneumonia incidence and other adverse reactions.
- Track regulatory progress for the same combination (RELVAR ELLIPTA) in the EU and Japan.
- Assess the impact of the LABA class warning on market adoption and potential litigation risks.